Today
Ansell overcomes Trump tariff hit with higher prices, swingeing cuts
The medical glove and protective surgical suits maker has outperformed expectations despite putting the cost of the trade restrictions at $113 million a year.
This Month
‘I’m very measured’: Sigma CEO’s global ambition for Chemist Warehouse
Vikesh Ramsunder says Chemist Warehouse’s international operations could one day “potentially” exceed the huge Australian store network.
Botanix Pharmaceuticals raises capital at 45pc discount
Fund managers have been wall-crossed for a roughly $30 million capital raising and a possible share purchase plan.
Cochlear shares hit three-year low on new implant delays
The medical device maker expects full-year earnings to land near the bottom end of its forecast range, and has written down its investment in Saluda.
Doctors warn against this popular wellness trend
Hyperbaric oxygen therapy has become popular with biohackers focused on longevity, health and improved performance. But medical experts say there are risks.
A2 Milk has rebuilt its brand. Now it faces a demographic tsunami
It’s been a wild ride for the man who permanently took over from Jayne Hrdlicka, but the infant formula giant is rebuilding in the face of China’s falling birth rate.
Billionaire Sam Hupert says AI will not terminate his business
Pro Medicus shares sank 24 per cent on Thursday after a solid profit result failed to convince investors it would be immune to disruption from AI.
‘It is not a crisis’: CSL’s interim boss pleads for investor patience
The global biotechnology firm reported a sharp fall in half-year earnings, announced more than $1 billion in write-downs and began a search for a new CEO.
CSL dumps CEO after horror year, triggering market sell-down
Paul McKenzie is retiring effective immediately after a series of setbacks for the biotech, just days before the company was due to release financial results.
CSL was our bluest blue chip. Now it looks chaotic
For the best part of a decade, the company was unimpeachable. But the sudden exit of chief executive Paul McKenzie underscores the new sense of chaos around the group.
Dodgy NDIS providers offering flights and cruises: ACCC
The competition watchdog says the scale of complaints it has received about “scam” NDIS providers threatens the safety of participants.
Project Port: Healthcare staffing biz hits the auction block
Alliance Nursing’s owners have called in advisors from McGrathNicol to shop the $98 million revenune-a-year business to potential acquirers.
The suburbs where NDIS providers outnumber patients
These suburban Sydney streets are clogged with NDIS providers within a national system where fraud and wastage rule.
Healthscope becomes not-for-profit to keep hospital empire intact
Lenders have agreed to keep 31 assets together, but landlords warn it is not a done deal and sends taxpayers dollars to offshore hedge funds.
Major study debunks statins side effect fears
Millions of Australians using statins to combat bad cholesterol can rest easier after scientists dispelled common concerns over side effects.
Healthscope set to go not-for-profit as PEP bows out of hospital race
The country’s second-largest private hospital business has been in the midst of a long-running sales process after its former owner, Brookfield, pulled the pin.
Telix chairwoman quits after brutal year, shares sink
The radiopharmaceutical giant says that Tiffany Olson is leaving for personal reasons, with Caledonia’s Mark Nelson stepping in.
How protein rose to the top of the food chain
Eating more protein is in vogue, thanks to popular diets, the power of social media influencers and the advent of GLP-1 weight-loss drugs.
Parents, schools to take on autism care under Labor’s NDIS alternative
Children with mild autism will not need a diagnosis to access the Thriving Kids scheme when Labor’s alternative to the NDIS rolls out from next month.
Starving to death: Malnutrition risk from weight loss drugs
An Australian-led study suggests dietary intake and nutrition are being ignored in global studies of GLP-1s, which could result in malnutrition, even scurvy.
PYC Therapeutics launches $600m-plus cash call, hires two banks
The listed biotech has a pipeline of RNA-based drugs to treat rare conditions such as polycystic kidney disease.
Vitamins group Homart Pharmaceuticals readies $100m IPO
The vitamins and beauty products business is working with advisers at Canaccord Genuity and Morgans Financial on a non-deal roadshow.
January
Wait time for aged care services blows out to 245 days
Productivity Commission data shows wait times for aged care services rose last financial year, but Labor says there are signs things are improving.
Healthscope receivers to reject landlord attack on not-for-profit plan
Tino La Spina’s push to restructure the hospital operator into a not-for-profit company has support from receivers McGrathNicol.
Mayne Pharma to return to court to fight Cosette for failed bid costs
The Adelaide-based company faces pressure from shareholders to restore value after share price sank on a failed bid.
